Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | DB-1419 |
| Trade Name | |
| Synonyms | DB 1419|DB1419 |
| Drug Descriptions |
DB-1419 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting CD274 (PD-L1) and CD276 (B7-H3) linked to a DNA topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and inhibits tumor growth (Eur J Cancer 211 (2024): 114702; Cancer Res (2025) 85 (8_Supplement_2): CT121). |
| DrugClasses | CD276 Antibody 21 PD-L1/PD-1 antibody 133 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| DB-1419 | DB-1419 | 0 | 1 |